Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 6, 2025
Product Development
Telix’s end-to-end radiopharma ambitions
With a NASDAQ listing, diagnostic revenues, and clinical therapeutics, logistics-forward company aims to own entire disease journey
BioCentury | Apr 29, 2024
Deals
Ono’s $2.4B Deciphera buy adds two cancer therapies, grows U.S. presence
With end of Opdivo’s exclusivity on the horizon, Japanese pharma continues to take steps in global expansion
BioCentury | Feb 4, 2023
Market Access
Rare diseases, MNCs grow presence on China’s NRDL
Even with big price reductions, China’s national reimbursement list is a lure for drug developers around the globe
BioCentury | Jan 24, 2023
Regulation
Jan. 23 Quick Takes: TheracosBio’s SGLT2 inhibitor approved for Type II diabetes
Plus: FDA convenes panel for tofersen and updates from Blueprint, Iovance, Clinigen and more
BioCentury | Nov 23, 2021
Product Development
Nov. 22 Quick Takes: GSK, Arrowhead in deal for NASH candidate
Plus Zenas-Xencor, BioCryst, Deciphera, bluebird, Exelixis and more
BioCentury | Jun 30, 2021
Product Development
Side-by-side look at BeiGene and Zai’s cancer pipelines: Data Byte
Apart from PD-1 and PARP inhibitors, the cancer pipelines of two of China’s leading public biotechs BeiGene and Zai hold few overlapping targets, though the two are exploring a similar range of
BioCentury | Jun 18, 2021
Regulation
June 18 Quick Takes: Orphazyme looks ahead to EMA decision following complete response letter; plus Chi-Med, BeiGene, Blueprint and Agenus
Orphazyme A/S (NASDAQ:ORPH; CSE:ORPHA) is looking ahead to a CHMP opinion in 4Q21 for arimoclomol after receiving a complete response letter from FDA for the inducer of Hsp70 to treat Niemann-Pick
BioCentury | Jun 1, 2021
Deals
Drawing on strength of balance sheet, Zai enters KRAS field in China via Mirati deal
With growing cash reserves, Zai is paying $65 million up front for local rights to Mirati’s KRAS program
BioCentury | Mar 31, 2021
Regulation
March 31 Quick Takes: Basket of EU approvals includes MS, SMA drugs; plus Amarin, AbbVie, Cara-Vifor
The European Commission approved Kesimpta ofatumumab from Novartis AG (NYSE:NVS; SIX:NOVN) to treat relapsing forms of multiple sclerosis. The subcutaneously administered drug was originally
Items per page:
1 - 10 of 111